Akarirmak, ÜlküKoçyiğit, HikmetEskiyurt, NurtenEsmaeilzadeh, SinaKuru, ÖmerYalçinkaya, Ebru YilmazPeker, Özlen2024-09-192024-09-1920161017-995Xhttps://doi.org/10.1590/S0080-623420160000500008https://hdl.handle.net/20.500.12483/14569Objective: In our study, we aimed to evaluate the influence of training on compliance and persistence with bisphosphonate treatment given on a weekly vs. monthly basis in postmenopausal osteoporosis patients. Methods: A total of 979 patients with postmenopausal osteoporosis (mean age: 63.2 ± 7.2 years) were included in this national, multicenter, prospective non-interventional observational cohort registry study. Patients were randomized into training (n = 492, 50.3%, mean age: 63.4 ± 7.2 years) and control (n = 487, 49.7%, mean age: 63.0 ± 7.1 years) groups. Patients in each intervention group were given weekly (44.9% and 44.6% for training and control subjects, respectively) or monthly (55.1% and 55.4%, respectively) bisphosphonate regimens. After the initial visit, patients were followed up at three-month intervals throughout 12 months of treatment for evaluation of persistence, compliance and adverse events. Results: On average, 79.4% of the patients were persistent with the treatment with a mean of 350.4 days of duration during the 12-month follow-up period. The mean compliance in the compliant and fully compliant group remained at an average of 86.6%. No significant difference was detected between the training and control groups in terms of compliance and persistence. Significantly longer persistence (360.0 ± 89.0 vs. 345.0 ± 108.0 days; p = 0.035), higher percentage of persistent patients (83.4% vs. 74.2%; p = 0.012) and higher compliance rates (88.8% vs. 83.3%; p = 0.002) were noted in monthly regimen patients in comparison to those given weekly regimen. © 2016 Turkish Association of Orthopaedics and Traumatology.eninfo:eu-repo/semantics/openAccessBisphosphonateComplianceDosing regimenOsteoporosisPersistenceTrainingArticle50459259910.1590/S0080-623420160000500008275246712-s2.0-84994106436Q2